Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Atreca Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BCEL
Over the counter
8731
https://www.atreca.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Atreca Inc
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
- Dec 26th, 2023 1:30 pm
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
- Nov 14th, 2023 9:30 pm
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
- Sep 21st, 2023 12:00 pm
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
- Aug 14th, 2023 2:51 pm
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
- Aug 10th, 2023 8:05 pm
3 Penny Stocks to Catapult You Into the Millionaires’ Club
- Jul 13th, 2023 5:03 pm
We're A Little Worried About Atreca's (NASDAQ:BCEL) Cash Burn Rate
- Jun 28th, 2023 12:57 pm
Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting
- Jun 5th, 2023 12:00 pm
Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments
- May 10th, 2023 8:05 pm
Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting
- Apr 26th, 2023 8:05 pm
Scroll